Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 28, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase transaction:
- Shares Purchased: 2,500,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,377.9851 pence per share.
- Treasury Holdings: Following the purchase, the Company holds 278,582,678 shares in Treasury.
- Shares in Issue: 5,731,755,304 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the open market purchase of 2,500,000 shares. This transaction increased the total number of shares held in Treasury. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed in this report.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,731,755,304) for calculating disclosure thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
- Confirm the updated Treasury share count of 278,582,678.
- Note that this filing is a notification of a share buyback and does not contain operational or financial performance results.